{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T08:53:40Z","timestamp":1768640020338,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"29-30","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.vaccine.2011.04.084","type":"journal-article","created":{"date-parts":[[2011,5,21]],"date-time":"2011-05-21T01:49:55Z","timestamp":1305942595000},"page":"4771-4777","source":"Crossref","is-referenced-by-count":58,"title":["Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague"],"prefix":"10.1016","volume":"29","author":[{"given":"E.D.","family":"Williamson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.J.","family":"Packer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.L.","family":"Waters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.J.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Dyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hartings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Twenhafel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.L.M.","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.04.084_bib0005","first-page":"86","article-title":"Plague Democratic Republic of the Congo","volume":"80","author":"WHO","year":"2005","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/CMR.10.1.35","article-title":"Yersinia pestis\u2014etiologic agent of plague","volume":"10","author":"Perry","year":"1997","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0015","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.vaccine.2005.12.057","article-title":"Plant-made subunit vaccine against pneumonic and bubonic plague is orally immunogenic in mice","volume":"24","author":"Alvarez","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1128\/MMBR.25.3.249-261.1961","article-title":"Pneumonic plague","volume":"35","author":"Meyer","year":"1961","journal-title":"Bacteriol Rev"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0025","series-title":"CRC handbook series in zoonoses 1979. Section A. Bacterial, rickettsial and mycotic diseases","first-page":"515","article-title":"Plague","author":"Poland","year":"1979"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0030","first-page":"237","article-title":"Surveillance and control of bubonic plague in the United States","volume":"50","author":"Barnes","year":"1982","journal-title":"Symp Zool Soc Lond"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0035","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.1967.03130170165036","article-title":"Pneumonic plague in an untreated plague vaccinated individual","volume":"202","author":"Cohen","year":"1967","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0040","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1574-695X.1995.tb00196.x","article-title":"A new improved sub-unit vaccine for plague: the basis of protection","volume":"12","author":"Williamson","year":"1995","journal-title":"FEMS Immun Med Micro"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0045","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0264-410X(96)00303-9","article-title":"A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunised animals against pneumonic plague","volume":"15","author":"Williamson","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0050","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0264-410X(00)00159-6","article-title":"A single dose sub-unit vaccine protects against pneumonic plague","volume":"19","author":"Williamson","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0055","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1128\/IAI.64.11.4580-4585.1996","article-title":"Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis","volume":"64","author":"Anderson","year":"1996","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0060","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1128\/IAI.64.6.2180-2187.1996","article-title":"Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and an Escherichia coli recombinant strain and efficacy against lethal plague challenge","volume":"64","author":"Andrews","year":"1996","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0065","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1021\/bp050098r","article-title":"Design and testing for a non-tagged F1\u2013V fusion protein as vaccine antigen against bubonic and pneumonic plague","volume":"21","author":"Powell","year":"2005","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0070","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1128\/IAI.73.6.3598-3608.2005","article-title":"Human immune response to a plague vaccine comprising recombinant F1 and rV antigens","volume":"73","author":"Williamson","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.micpath.2006.09.003","article-title":"Immunogenicity of the rF1+rV vaccine with the identification of potential immune correlates of protection","volume":"42","author":"Williamson","year":"2007","journal-title":"Microb Pathogen"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0080","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0264-410X(00)00108-0","article-title":"Protection conferred by a fully recombinant sub-unit vaccine against Yersinia pestis in male and female mice of four inbred strains","volume":"19","author":"Jones","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0085","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0264-410X(98)80110-2","article-title":"Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1\u2013V antigen fusion protein vaccine","volume":"16","author":"Heath","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0090","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1016\/j.vaccine.2009.01.050","article-title":"A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague","volume":"26","author":"Chichester","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0095","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1128\/CVI.00333-08","article-title":"Flagellin-F1\u2013V fusion protein is an effective plague vaccine in mice and two species of nonhuman primate","volume":"16","author":"Mizel","year":"2009","journal-title":"Clin Vac Immunol"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0100","unstructured":"EMEA guidance CPMP\/EWP\/463\/97."},{"key":"10.1016\/j.vaccine.2011.04.084_bib0105","unstructured":"FDA guidance 21CFR 601.90-95. Evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Fed Register 2002;67:37988\u201398."},{"key":"10.1016\/j.vaccine.2011.04.084_bib0110","first-page":"156","article-title":"Pathology of experimental pneumonic plague produced by Fraction1 positive and Fraction1 negative Yersinia pestis in African Green monkeys","volume":"120","author":"Davis","year":"1996","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0115","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1128\/IAI.01296-09","article-title":"Milestones in progression of primary pneumonic plague in cynomolgus macaques","volume":"78","author":"Koster","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0120","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1128\/IAI.00699-08","article-title":"Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague","volume":"76","author":"Cornelius","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0125","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1128\/IAI.65.11.4476-4482.1997","article-title":"Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunisation","volume":"65","author":"Hill","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0130","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.1016\/j.vaccine.2009.09.061","article-title":"N255 is a key residue for recognition by a monoclonal antibody which protects against Yersinia pestis infection","volume":"27","author":"Hill","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0135","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2353\/ajpath.2009.071168","article-title":"Pneumonic plague pathogenesis and immunity in Brown Norway rats","volume":"174","author":"Anderson","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0140","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1128\/CVI.00398-06","article-title":"Development of in vitro correlate assays of immunity to infection with Yersinia pestis","volume":"14","author":"Bashaw","year":"2007","journal-title":"Clin Vac Immunol"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0145","first-page":"7748","volume":"28","author":"Fellows","year":"2010","journal-title":"Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1 V) Vaccine"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0150","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1128\/CVI.00091-08","article-title":"Modified caspase-3 assay indicates correlation of caspase-3 activity with immunity of nonhuman primates to Yersinia pestis infection","volume":"15","author":"Welkos","year":"2008","journal-title":"Clin Vac Immunol"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0155","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jplph.2010.06.012","article-title":"Transgenic carrot tap roots expressing an immunogenic F1\u2013V fusion protein from Yersinia pestis are immunogenic in mice","volume":"168","author":"Rosales-Mendoza","year":"2011","journal-title":"J Plant Physiol"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0160","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0264-410X(97)00249-1","article-title":"Intranasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse","volume":"16","author":"Eyles","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0165","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1016\/j.vaccine.2005.12.016","article-title":"Protection against bubonic and pneumonic plague with a single dose microencapsulated sub-unit vaccine","volume":"24","author":"Elvin","year":"2006","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2011.04.084_bib0170","doi-asserted-by":"crossref","first-page":"e17642","DOI":"10.1371\/journal.pone.0017642","article-title":"Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases","volume":"6","author":"Ulery","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0175","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.vaccine.2005.09.052","article-title":"Intranasal Protollin\u2122\/F1\u2013V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection","volume":"24","author":"Jones","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0180","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1016\/j.vaccine.2004.02.049","article-title":"Immunisation against plague by transcutaneous and intradermal application of sub-unit antigens","volume":"22","author":"Eyles","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0185","doi-asserted-by":"crossref","first-page":"7984","DOI":"10.1016\/j.vaccine.2007.09.030","article-title":"Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens","volume":"19","author":"Uddowla","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0190","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1128\/IAI.65.5.1926-1930.1997","article-title":"Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an Aro A mutant of Salmonella typhimurium induces high level protection against plague","volume":"65","author":"Titball","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0195","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1006\/mpat.1997.0141","article-title":"Expression of an F1\/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague","volume":"23","author":"Leary","year":"1997","journal-title":"Microb Pathogen"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0200","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/1874126600802010052","article-title":"The use of an oil-based delivery formulation for both oral and parenteral vaccination","volume":"2","author":"Domingos","year":"2008","journal-title":"Open Drug Deliv J"},{"key":"10.1016\/j.vaccine.2011.04.084_bib0205","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1016\/j.vaccine.2010.06.020","article-title":"Protection against pneumonic plague following oral immunization with a non-replicating vaccine","volume":"28","author":"Jones","year":"2010","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11006396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11006396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T11:12:17Z","timestamp":1592565137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11006396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":41,"journal-issue":{"issue":"29-30","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0264410X11006396"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.04.084","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}